About Nuvation Bio Inc.
http://www.nuvationbio.comNuvation Bio, Inc. is a biopharmaceutical company tackling some of the unmet needs in oncology by developing differentiated and novel therapeutic candidates. Its proprietary portfolio includes six novel and mechanistically distinct oncology therapeutic product candidates, each targeting some of the most difficult-to-treat types of cancer.
CEO
David T. Hung
Compensation Summary
(Year 2022)
Ratings Snapshot
Rating : B
Price Target
Institutional Ownership
ECOR1 CAPITAL, LLC
Shares:963.33K
Value:$55.87K
DECHENG CAPITAL LLC
Shares:646.06K
Value:$37.47K
GREENLAND CAPITAL MANAGEMENT LP
Shares:344.66K
Value:$19.99K
Summary
Showing Top 3 of 28
About Nuvation Bio Inc.
http://www.nuvationbio.comNuvation Bio, Inc. is a biopharmaceutical company tackling some of the unmet needs in oncology by developing differentiated and novel therapeutic candidates. Its proprietary portfolio includes six novel and mechanistically distinct oncology therapeutic product candidates, each targeting some of the most difficult-to-treat types of cancer.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q3-2025 | $13.12M ▲ | $66.2M ▲ | $-55.79M ▲ | -425.24% ▲ | $-0.16 ▲ | $-54.76M ▲ |
| Q2-2025 | $4.83M ▲ | $65.85M ▲ | $-59.01M ▼ | -1.22K% ▲ | $-0.17 ▼ | $-58.23M ▼ |
| Q1-2025 | $3.08M ▼ | $59.99M ▲ | $-53.24M ▼ | -1.73K% ▼ | $-0.16 ▼ | $-52.87M ▼ |
| Q4-2024 | $5.71M ▲ | $55.44M ▲ | $-49.45M ▼ | -865.79% ▲ | $-0.15 | $-49.14M ▼ |
| Q3-2024 | $727K | $47.31M | $-41.21M | -5.67K% | $-0.15 | $-40.93M |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q3-2025 | $549.04M ▼ | $601.56M ▼ | $275.68M ▲ | $325.88M ▼ |
| Q2-2025 | $607.72M ▲ | $647.23M ▲ | $274.32M ▲ | $372.91M ▼ |
| Q1-2025 | $461.68M ▼ | $492.49M ▼ | $73.03M ▼ | $419.46M ▼ |
| Q4-2024 | $502.69M ▼ | $540.63M ▼ | $76.84M ▲ | $463.79M ▼ |
| Q3-2024 | $549.13M | $571.58M | $68.86M | $502.71M |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q3-2025 | $-55.79M ▲ | $-52.89M ▼ | $-96.62M ▼ | $501K ▼ | $-149.07M ▼ | $-52.9M ▼ |
| Q2-2025 | $-59.01M ▼ | $-48.18M ▼ | $54.88M ▲ | $193.42M ▲ | $199.99M ▲ | $-48.36M ▼ |
| Q1-2025 | $-53.24M ▼ | $-42.63M ▲ | $54.18M ▲ | $548K ▲ | $12.25M ▲ | $-42.7M ▲ |
| Q4-2024 | $-49.45M ▼ | $-46.3M ▼ | $51.77M ▲ | $-900K ▲ | $5.69M ▲ | $-46.29M ▼ |
| Q3-2024 | $-41.21M | $-31.09M | $29.12M | $-1.54M | $-4.25M | $-31.23M |
Revenue by Products
| Product | Q1-2025 | Q2-2025 | Q3-2025 |
|---|---|---|---|
 License | $0 ▲ | $0 ▲ | $10.00M ▲ |
 Product | $0 ▲ | $0 ▲ | $10.00M ▲ |
 Product Revenue | $0 ▲ | $0 ▲ | $0 ▲ |
 Royalty Revenue | $0 ▲ | $0 ▲ | $0 ▲ |
Revenue by Geography
| Region | Q4-2024 | Q2-2025 | Q3-2025 | Q1-2025 |
|---|---|---|---|---|
 CHINA | $10.00M ▲ | $0 ▼ | $0 ▲ | $0 ▲ |
 JAPAN | $0 ▲ | $0 ▲ | $0 ▲ | $0 ▲ |
 UNITED STATES | $0 ▲ | $0 ▲ | $10.00M ▲ | $0 ▼ |
CEO
David T. Hung
Compensation Summary
(Year 2022)
Ratings Snapshot
Rating : B
Price Target
Institutional Ownership
ECOR1 CAPITAL, LLC
Shares:963.33K
Value:$55.87K
DECHENG CAPITAL LLC
Shares:646.06K
Value:$37.47K
GREENLAND CAPITAL MANAGEMENT LP
Shares:344.66K
Value:$19.99K
Summary
Showing Top 3 of 28